Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
From a single weekly injection
Scott Galloway addresses concerns about muscle loss on GLP-1 drugs and explains why hes still bullish, unpacks the financial and emotional strain of supporting aging family members, and makes the case for putting the pedal down on your career before its too late
The hallmark of this condition is a cycle of chronic inflammation
Key Points Oxyntomodulin and peptide tyrosinetyrosine (PYY) are gut peptides that are released postprandially Oxyntomodulin and PYY act as satiety signals via effects on appetite centers such as the hypothalamus and brainstem Exogenous administration of oxyntomodulin or PYY 336 reduces energy intake, adiposity and body weight in animals Several studies suggest that drug therapy based on these hormones could be an effective treatment for human obesity This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 119.00 per year only 9.92 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
US$ 23.30
US$ 28.83
US$ 27.15
US$ 27.09
